Objective: In this cross-sectional study, we aimed to evaluate brain structural abnormalities in relation to glial activation in the same cohort of participants.
The pathophysiology of amyotrophic lateral sclerosis (ALS) is poorly understood, but the immune system has increasingly been implicated in the pathogenesis of the disease.
1 Activated microglia are increased in postmortem brain and spinal cord tissue from people with ALS, and the number of activated microglia correlates with the rate of disease progression. 2 A strong proinflammatory signature in ALS is found from gene expression profiling of postmortem spinal cord tissue. 3 In addition, proinflammatory cytokines are increased in CSF. 4 Studies in the widely used SOD1
G93A transgenic ALS mouse model showed activated microglia near the motor neurons before the onset of weakness and the inflammatory response in these mice correlates with disease progression. 5 [ 11 C]-PBR28 is a PET radiotracer that selectively binds to the translocator protein (TSPO). TSPO is upregulated in activated microglia and reactive astrocytes. 6, 7 We previously reported increased glial activation measured by [ 11 C]-PBR28 uptake in the motor cortices in people with ALS. 8 We hypothesize that glial activation measured by [ 11 C]-PBR28 binding is anatomically correlated with microstructural tissue damage including subcortical white matter changes and cortical thinning. Our hypothesis is anchored on ALS postmortem and mouse model pathology showing active microglia and astrogliosis surrounding degenerating motor neurons. 5, 9 This study demonstrates the value of simultaneous MR/PET in vivo imaging techniques in measuring structural and molecular changes in patients with ALS compared to healthy controls (HC).
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the local institutional review board and the Radioactive Drug Research Committee. All participants provided written informed consent for study participation.
Study participants. In this study, we investigated a cohort of previously reported participants. 8 The participants are 10 individuals diagnosed with ALS and 10 HC matching in age, sex, and [ 11 C]-PBR28 binding affinity. Demographic information and clinical assessment are summarized in table 1. [ 11 C]-PBR28 binding affinity studies using postmortem human brain tissue revealed substantial variation (low, mixed, high) in binding affinity of [ 11 C]-PBR28 for TSPO. 10 This variation is due to a single nucleotide polymorphism (rs6971) in the gene encoding TSPO, which causes a substitution of threonine and alanine at position 147 (Ala147Thr). All participants were tested for this polymorphism and groups were matched for the number of medium and high affinity binders.
Participants with ALS were diagnosed with possible, probable, probable laboratory-supported, or definite ALS, according to modified El Escorial criteria. 11 None of the ALS participants had clinical signs of frontotemporal dementia and none of the study participants were taking benzodiazepines, immunosuppressants, or anti-inflammatory medications.
ALS evaluation. The Upper Motor Neuron Burden Scale (UMNB) was obtained from all participants with ALS. This scale measures the following deep tendon reflexes: biceps, brachioradialis, triceps, knee jerk, ankle jerk (scores 0-4); and pathologic reflexes: Hoffman, Babinski, and jaw jerk (present, 1; or absent, 0). All reflexes are assessed bilaterally except for jaw jerk, producing a scale ranging between 0 and 45. Higher scores indicate a greater extent of upper motor neuron dysfunction. The Revised ALS Functional Rating Scale (ALSFRS-R) was administered to all participants with ALS.
12 ALSFRS-R is a quantitative measure of ALS-related physical and functional deficits and ranges from 0 to 48, with lower scores representing more disability. 11 C]-PBR28 was produced in-house as described previously. 8 The radioligand was injected as slow IV bolus, with a mean administered dose of 430 MBq 6 34 for participants with ALS and 424 MBq 6 42 for HC.
MR/PET data acquisition. Imaging data were collected at the Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using a Siemens 3T Magnetom Tim Trio scanner (Siemens, Erlangen, Germany). This magnetic resonance (MR) scanner is equipped with an 8-channel head coil and a dedicated brain avalanche photodiode-based PET scanner operating in the bore of the 3T whole-body MR scanner. MRI scans included diffusion-weighted imaging and a T1-weighted 3D multiecho magnetization-prepared rapid acquisition gradient echo. The acquisition parameters are listed in table e-1 at Neurology.org. A multislice single-shot echo planar spin echo pulse sequence was employed to obtain measurements at a diffusion weighting of b 5 3,000 s/mm 2 and the diffusionencoding directions were distributed uniformly over the surface of a sphere using electrostatic repulsion. Images were acquired using a single-shot, spin echo, and echo planar imaging sequence with twice refocused spin echo diffusion preparation (Q-ball imaging). Each series included 60 images acquired with diffusion weighting and 8 noncollinear directions. PET data and structural scans were acquired simultaneously for all 20 participants and diffusion data were acquired for all but 4 HC participants due to scanning time limitations.
MR/PET data preprocessing. PET images were reconstructed as previously described. 8 The images of standardized uptake value (SUV) were created for radioactivity in the field of view 60-90 minutes post radioligand injection. These images were normalized to the whole brain mean (SUV ratio [SUVR] 60-90 minutes) as previously reported. 8, 13 Preprocessing of raw diffusion data was performed using FMRIB software library (FSL; Oxford, UK) version 5.0.7.
14 The following measures were applied to determine whether diffusion tensor imaging (DTI) scans acquired were of sufficient quality 15 : percentage of slices with signal dropout score and motion parameters as well as signal to noise ratio evaluation for every scan. Cortical 16 Voxelwise analyses were performed by FSL randomise 17 using threshold-free cluster enhancement 18 and 5,000 permutations. The resultant statistical maps were family-wise error (FWE) adjusted and thresholded to p FWE , 0.05. The anatomical locations were determined by using the JHU White-Matter Tractography Atlas. 19 In addition, age was included as a covariate in these analyses, to control for the potential confounding effect of this factor.
Precentral gyrus (PCG) region of interest (ROI) analyses. The predetermined ROIs for the left and right PCG for both the gray matter and the underlying white matter were derived from the automatic T1 segmentation in Freesurfer. 20 Those ROIs were used to estimate FA, diffusivities, and [
11 C]-PBR28 SUVR. All statistical analyses were performed using JMP pro 12.0.1 (SAS Institute Inc., Cary, NC). Between-group differences were tested using independent samples t test. Effect size (Cohen d and 95% confidence interval) was calculated based on differences between groups. Spearman correlation coefficients were calculated.
DTI-derived corticospinal tract (CST) tractography. Depending on TBSS findings and in order to obtain a mask for the upper part of CST, our other ROI, local probabilistic tractography of CST was carried out using FSL tools. We used masks from the output of T1 segmentation in Freesurfer as seed and target. The seed was located in the cortical parcellate of the PCG and the target mask at the level of the basal ganglia. FMRIB's linear image registration tool (FLIRT) was used to linearly transform each FA and non-FA map to T1 and the reverse matrix was applied to move each mask (seed and target) from T1 to diffusion space. BedpostX/ProbTrackX algorithm was run with its default parameters: 2-fiber model per voxel, 5,000 probabilistic streamlines for each tract with a fixed separation distance of 0.5 mm between successive points to generate the underlying white matter connectivity data. 21 In order to measure [ 11 C]-PBR28 SUVR within CST, the CST probabilistic distribution map (derived from ProbTrackX and thresholded for values .0.20 to constrain the resultant pathway to white matter voxels) was used as an ROI. The analysis was conducted in MNI152 standard space. FLIRT and FMRIB's nonlinear image registration tool were used to transform each SUVR map to MNI152 and FLIRT was used to linearly transform each DTI map to MNI152. Each CST ROI was also transformed into MNI152. DISCUSSION We found anatomical links between molecular changes (expression of the glial marker TSPO) and structural anomalies (decreased FA, increased diffusivity and cortical thinning) in patients with ALS compared to HC. We previously provided in vivo evidence for glial activation in the motor cortices and subcortical white matter in ALS using [ 11 C]-PBR28 PET. 8 Here, we report altered white and gray matter integrity in the same regions of increased glial activation, in the same cohort of participants. Specifically, increased [ 11 C]-PBR28 uptake in the motor cortex (gray matter) in participants with ALS was associated with cortical thinning and loss of tissue integrity as indicated by decreased FA and increased diffusivity. All 3 measures including In this cohort, structural abnormalities and increased glial activation were more statistically significant in the left PCG. Unilateral effects have been described in the literature (e.g., only in the right PCG, [24] [25] [26] [27] only in the left PCG, 28 or bilateral motor cortices [29] [30] [31] [32] [33] ). Several factors can contribute to the laterality of our results, as well as those reported by groups. These factors include different phenotypes of study populations and the thresholds applied to the statistical maps. When examining the data using lower statistical thresholds, it becomes apparent that both hemispheres are affected. Therefore, it is possible that statistical threshold may be partly responsible for the observed laterality. On the other hand, the colocalization we saw in this study between different imaging modalities strengthens the relevance of these results and demonstrates the power of multimodal neuroimaging approaches.
Our results indicate a mechanistic link between tissue integrity and glial activation in people with sporadic ALS. In neuroimaging studies, combining multiple advanced neuroimaging modalities has contributed to a better understanding of disease mechanism in ALS. For example, using DTI and MR spectroscopic imaging (MRSI) to evaluate structural and neurochemical characteristics of brain in ALS has demonstrated in vivo evidence of neuroinflammation, gliosis, and degeneration of the motor cortices and CST. 34, 35 Although MRSI metabolites (e.g., myo-inositol) are not specific for neuroinflammation or gliosis, the relationship between these measures and the metrics of DTI is interesting. On the other hand, MRI measures and the molecular markers of inflammation assessed with PET have been reported in few diseases. For example, in secondary progressive multiple sclerosis, adenosine A2A receptor availability, which is upregulated during inflammation, was correlated with FA in the normal-appearing white matter. 36 This is additional evidence highlighting the link Table 2 Diffusion tensor imaging metrics, cortical thickness, and [ between increases in CNS inflammation and decreases in tissue integrity. Cortical thinning and decreases in FA and increased diffusivity have been reported previously in ALS cross-sectional studies. 37 Here, we were able to replicate these findings, and in addition, show colocalization with a molecular marker of glial activation. One can speculate that we are observing both cause and effect of neurodegeneration. In other words, when cortical motor neurons degenerate, they lose their intrinsic axons, which may trigger regional reactive glial activation, and vice versa. The proinflammatory mediators expressed by activated glia can lead to axonal loss and neurodegeneration. 38 It is debated whether glial activation is protective or toxic in neurodegeneration; however, prior studies in ALS mouse models suggest that inflammation and glial activation play an important role in accelerating disease progression. 39, 40 In this study, the structural and molecular changes of neuroimaging analyses were strongly correlated with clinical signs of upper motor neuron dysfunction, demonstrating the clinical relevance of our findings. On the other hand, the rate of disease progression did not correlate with the imaging findings. It is possible that the relationship between the anatomical changes and disease progression is nonlinear or the sample size is too small to show statistical significance. Future longitudinal studies with and without therapeutic interventions are needed to address the temporal sequence of events, including changes in FA within gray and white matter regions, inflammation, cortical thinning, and clinical disease progression.
Small sample size is the major limitation of this study. We consider our results as exciting preliminary data that need further replication in larger studies. At the same time, our data demonstrate concordance across multiple imaging modalities that solidifies the validity of our findings within this small cohort.
Our findings, although preliminary, could still have direct implications on clinical drug development for ALS and other neurodegenerative disorders. Historically, most phase II clinical trials that assess preliminary efficacy in ALS have been significantly underpowered because of the use of clinical measures such as ALSFRS-R as primary trial outcomes. This phenomenon resulted in a number of false-positive phase II trials of drug candidates that failed in later and more expensive stages of development. Using molecular outcomes such as [ 11 C]-PBR28-PET in early phase II clinical trials could provide invaluable information on the biological activity of the experimental treatment at the relevant site of action (motor cortex, for example). This could also help with dose selection and eventually making go-no-go decisions based on molecular and mechanism-based evidence of target engagement.
